Effect of acupoint catgut embedding for simple obesity in adults: A randomized controlled double-blind trial

Acupoint catgut embedding (ACE) is considered an effective treatment for simple obesity, though high-quality clinical evidence remains lacking. To establish a solid evidence base in obesity management, well-designed studies are needed to verify both the short- and long-term efficacy and safety of ACE.

In this randomized controlled, double-blind trial, 120 patients with simple obesity were initially allocated to verum ACE (n = 60) or sham ACE group (n = 60) .One participant allocated to the verum group was excluded during screening for failing to meet BMI criteria (<24 kg/m²), resulting in a final cohort of 59 verum and 60 sham cases completing the 12-week intervention and 12-week follow-up. The primary outcome was the change in body weight from baseline to week 12. Secondary outcomes included body weight change at 12-week follow-up, cumulative weight change by week 24, changes in body mass index (BMI), body fat status, body circumference, and appetite indicators.

After the 12-week treatment, both groups showed varying degrees of weight loss, with the verum ACE group experiencing a significantly greater reduction compared to the sham group. At the 12-week follow-up, the visceral fat grade of the verum group was significantly greater than that of sham group. The waist, upper arm, and thigh girths in the verum group decreased significantly more than that in sham group; the reduction degree of waist-hip ratio was significantly better than that in the sham group at all time points. Additionally, the cumulative reduction in appetite factors was significantly higher in the verum group compared to the sham group.

ACE can significantly reduce body weight, and is both long-lasting and safe. It also has beneficial effects on fat distribution, body circumference, and appetite, making it a promising complementary therapy for simple obesity.

Chinese Clinical Trial Registry, ChiCTR2100046693.